

# ISID NEWS

An Official Publication of the International Society for Infectious Diseases



## ISID Executive Committee 2000–2002

J.P. Butzler (President)  
Belgium

K. Christiansen  
Australia

A. Geddes (Treasurer)  
United Kingdom

E. Gotuzzo (Past President)  
Peru

D. Kasper (President-Elect)  
USA

C.E. Nord  
Sweden

A. Ronald (Secretary)  
Canada

J. Shimada  
Japan

R. Wenzel  
USA

S.Y. Wong  
Singapore

J. Acar (Honorary Treasurer)  
France

Norman Stein  
(Executive Director) USA

Timothy Brewer  
(Program Director) USA

## ISID NEWS

### Editorial Board

Jacques Acar  
Alasdair Geddes

### Editorial Staff

Laurence Mialot  
Paul Guttry  
Jaylyn Olivo

181 Longwood Avenue  
Boston, MA 02115-5804 USA  
Telephone: (617) 277-0551  
1 (800) 779-8998  
Fax: (617) 731-1541  
E-mail: info@isid.org  
http://www.isid.org

## Meeting Challenges in Infectious Diseases: The 10th International Congress on Infectious Diseases in Singapore

by Tim Brewer, ISID Program Director

This March, approximately 4,000 infectious disease researchers and clinicians from around the world will gather in the dynamic city-state of Singapore for the 10th ICID.

As with previous congresses, the meeting will provide attendees with exciting updates of both research advances and new clinical practices in infectious diseases. Singapore, with its blend of Eastern and Western cultures, will provide an exciting and modern venue for the meeting.

The plenary sessions are once again the highlight of the meeting. They will start with the presentation of the Edward Kass lecture by Prof. Martin Blaser. This lectureship honors one of the founders of the International Society for Infectious Diseases. Prof. Blaser will discuss the plasticity of *Helicobacter pylori* during human colonization. *Helicobacter pylori* is one of the most common bacterial pathogens in the world and has been associated with duodenal ulcers, gastritis, and gastric carcinomas. Understanding the pathogenesis of *Helicobacter pylori* may one day lead to strategies for preventing this important public health pathogen. In the second plenary session, Prof. Charles Weissmann, one of the world's experts on prion diseases, will discuss the molecular biology of these unique infectious agents.

Human immunodeficiency virus and malaria continue to be responsible for tremendous mortality and morbidity throughout the world, particularly in tropical regions. Michel Caraël of UNAIDS will present the changing dynamic of the HIV pandemic, with particular emphasis on South East Asia. This talk is particularly apt for a meeting in Asia, as soon there may be more HIV-infected individuals in India than in any other country. Prof. Nicholas White of Oxford and Thailand will update Congress attendees on the challenges of treating multi-drug-resistant malaria. Despite advances in therapeutic agents to combat this parasite, it continues to cause millions of cases of disease and substantial deaths worldwide. In South East Asia and East Africa in particular, progressive resistance to antimalarial agents is a significant health problem.

Prof. Ruth Bishop, the discoverer of the rotavirus, will give a plenary presentation that will take the



audience from the pathophysiology of the rotaviral disease to efforts to develop a vaccine. Rotavirus is a leading cause of diarrhea worldwide, and an effective vaccine might substantially reduce childhood mortality due to diarrhea. The plenary lectures will conclude with reflections by Prof. Francis Waldvogel of Switzerland on past challenges and future opportunities in infectious diseases. Now, more than ever, infectious diseases are an important cause of preventable morbidity and mortality. Although it was once thought that infectious diseases would easily be controlled with antibiotics, it is now clear that the challenges of controlling infectious diseases are greater than ever. With his extensive international experience and distinguished career in this field, Prof. Waldvogel will provide an insightful presentation on what we might expect over the coming years.

The 10th ICID includes 41 symposia that will be held over the three days of the Congress. These symposia cover a broad array of issues in infectious diseases, and include topics pertinent to the clinicians and scientists from both the Western Pacific Region and the world as a whole. We cannot touch on all of the many highlights, but this newsletter includes an overview of the speakers and topics for the Congress.

continued on page 2



## PLENARIES

### 10th International Congress on Infectious Diseases • Plenaries

March 11–14, 2002 • Raffles City Convention Centre • Singapore

#### Rotavirus: From Bench to Vaccine

Ruth Bishop (Australia)

#### The Plasticity of *Helicobacter pylori* During Human Colonization

Martin J. Blaser (USA)

#### Dynamics of HIV Epidemics

Michel Caraël (Switzerland)



Ruth Bishop



Martin J. Blaser



Michel Caraël

#### Infectious Diseases in the 21st Century: Old Challenges and New Opportunities

Francis Waldvogel (Switzerland)

#### Molecular Biology of Prion Disease

Charles Weissmann (United Kingdom)

#### Challenges of Multi Drug Resistant Malaria

Nicholas J. White (Thailand)



Francis Waldvogel



Charles Weissmann



Nicholas J. White

### The 10th International Congress on Infectious Diseases in Singapore *continued from page 1*

The 10th ICID in Singapore will bring together internationally recognized speakers to present topics ranging from the management of bone infections to the determinants of Dengue viral virulence that should be of interest to almost everyone in the field of infectious diseases. In addition to the plenary sessions and the symposia, the ICID also will have approximately 750 posters of original research from investigators from around the world. The poster sessions will be held each day of the Congress during a time dedicated for poster viewing. As with previous congresses, there also will be lunchtime workshops and meet-the-expert sessions. The Society is delighted

to have the support and involvement of the pharmaceutical industry in the Congress. There are a number of company-organized satellite symposia addressing important issues, such as the management of hepatitis, innovative strategies for approaching gram-positive pathogens, and appropriate antibiotic choices for empiric coverage situations.

The 10th ICID is a great opportunity to be updated on developments in the fast-evolving field of infectious diseases, and all the while enjoying the hospitality of Singapore and the beauty and excitement of this international city. ❖

## 10th International Congress on Infectious Diseases • Satellite Symposia

March 11–14, 2002 • Raffles City Convention Centre • Singapore

### **Hepatitis Disease Management— Integrating Prevention, Diagnostics and Therapeutics**

*Pre-Congress Satellite Symposium sponsored by GlaxoSmithKline*

Monday, March 11, 2002 • 13:00 to 16:00hrs • Sophia & Olivia Rooms

- Hepatitis Disease Management: A Comprehensive Prevention, Diagnosis and Treatment Program—Past, Present, and Future  
Francis André (Belgium)
- Therapeutic Advances in Chronic Hepatitis B  
Ching Lung Lai (China)
- Economic Benefits of Treating Chronic Hepatitis B with Lamivudine  
Larry Lacey (United Kingdom)
- Overview of Country-specific Hepatitis Disease Management Programs:
  - The Malaysian Experience  
Nor Shahidah (Malaysia)
  - The Hong Kong Experience  
Betty Young (China)
- Importance and Benefits of Hepatitis A Prevention in Chronic Liver Disease (CLD) Patients  
Graham Cooksley (Australia)

### **Innovative Strategies in an Evolving World of Gram-Positive Pathogens**

*Dinner Satellite Symposium sponsored by Pharmacia*

Tuesday, March 12, 2002 • 18:00 to 22:00hrs • Canning Room

- Bacterial Pathogenicity—Why Are Some Resistant Strains More Successful Than Others?  
David M. Livermore (United Kingdom)
- Strategies for Infections in the Intensive Care Unit  
Pramod M. Shah (Germany)
- Post-Surgical Infections  
Joseph S. Solomkin (USA)
- Linezolid Versus Standard Therapy—Are New Antibiotics Better Than Glycopeptides?  
Mark H. Wilcox (United Kingdom)
- Update on Linezolid Safety Profile  
Sue K. Cammarata (USA)

### **Bacterial Eradication—Rationale for Antimicrobial Assessment**

*Dinner Satellite Symposium sponsored by GlaxoSmithKline*

Tuesday, March 12, 2002 • 18:30 to 22:00hrs • Olivia Room

- Welcome and Introduction: Goals of Antimicrobial Therapy  
Jae-Hoon Song (Republic of Korea)
- Why do we Need to Eradicate Pathogens in Respiratory Tract Infection?  
Javier Garau (Spain)
- How can we Predict Bacterial Eradication?  
Michael R. Jacobs (USA)
- Achieving Bacterial Eradication  
Ron Dagan (Israel)
- Implications for Antimicrobial Prescribing  
Keith Klugman (South Africa/USA)

### **Do your Antimicrobial Options Meet your Needs?— Using the Best in Class for Appropriate Empiric Coverage**

*Dinner Satellite Symposium sponsored by Bayer AG*

Wednesday, March 13, 2002 • 18:00 to 20:00hrs • Olivia Room

- Can we Prevent the Hospitalization of Pneumonia Patients?  
Keith Klugman (South Africa/USA)
- Emerging Resistance Among Respiratory Pathogens  
Jae-Hoon Song (Republic of Korea)
- Pharmacokinetic Predictors of Clinical Outcome  
John Turnidge (Australia)
- Moxifloxacin IV—A Novel Parenteral Therapy for the Treatment of CAP  
Tom File (USA)
- Providing Clinical Confidence for Today's Infections  
Ron Grossman (Canada)



**SATELLITE  
SYMPOSIA**





## SYMPOSIA

# 10th International Congress on Infectious Diseases • Preliminary Program

March 11–14, 2002 • Raffles City Convention Centre • Singapore

**SYMPOSIA.** The following symposia are being organized.

*Please note that not all topics and speakers have been confirmed and are subject to change.*

### **Practical Issues in Emerging Infections**

**Co-Chairs:** Ai Ee Ling (Singapore)  
Helen Oh (Singapore)

#### **Emergence of Nipah Virus: How it Happened! Will We Have Another Epidemic?**

Kaw Bing Chua (Malaysia)

#### **Enterovirus 71:**

#### **How and Why Epidemics Occur**

Tzou-Yien Lin (Taiwan)

#### **Crisis on the Border: Rift Valley Fever Outbreak in Saudi Arabia and Yemen**

Tariq Ahmed Madani (Saudi Arabia)

#### **Containing Hemorrhagic Fever Epidemics: The Ebola Experience in Uganda**

Margaret Lamunu (Uganda)

### **Partnerships for Containing Antimicrobial Resistance: The WHO Global Strategy in Action in Low-Resource Countries**

*Organized in collaboration with the World Health Organization (WHO)*

**Co-Chairs:** Atef Shibl (Saudi Arabia)  
Po-Ren Hsueh (Taiwan)

#### **The Role of WHO in Coordinating a Global Response to Antibiotic Resistance**

Lindsay Grayson (Australia)

#### **National Strategies to Reduce Irrational Use of Antimicrobials to Decrease Costs and Antimicrobial Resistance**

Daniel Lew (Switzerland)

#### **Drug Policy and Essential Drugs: What are their Impact in Preventing and Controlling Antimicrobial Resistance?**

Kathy A. Holloway (Switzerland)

#### **International Societies and Antimicrobial Resistance: Bridging Global Policy and Local Actions**

King Holmes (USA)

### **New Strategies for the Management of Bone, Joint, and Prosthetic Infections—New Approaches to Old Problems**

**Co-Chairs:** Daniel Lew (Switzerland)  
Francis Waldvogel (Switzerland)

#### **Pathophysiology and Novel Medical Therapeutic Modalities of Prosthetic Joint Infections**

Daniel Lew (Switzerland)

#### **Diabetic Foot Infection**

AW Karchmer (USA)

#### **Evidence-Based Approach to the Use of Local and Oral Antibiotics in Chronic Osteomyelitis**

Jon T. Mader (USA)

#### **Where Zebras Tread: Management of Chronic Tropical Osteomyelitis**

Philip A. Thomas (India)

### **Mechanisms of Antibiotic Resistance**

**Co-Chairs:** Jacques Acar (France)  
Awa Kane-Aïdara (Senegal)

#### **Multiple Antibiotic Resistance: Bacterial Advantages and Risks in the Clinical Setting**

Keryn Christiansen (Australia)

#### **Overcoming Resistance in Gram-Positive Pathogens: The Role of Antibiotic Combinations**

Philippe Moreillon (Switzerland)

#### **Understanding the Bacterial Cell Wall: New Enzymatic Pathways, New Resistances, and New Targets for Antibiotics**

Joachim-Volker Hoeltje (Germany)

#### **Diversity of Beta-Lactamases: What is the Future for Beta-Lactamase Inhibitors?**

Patrice Nordmann (France)

### **Infection Control in Low-Resource Settings: Recognizing the Need**

*Organized in collaboration with the Asia Pacific Society of Infection Control (APASIC)*

**Co-Chairs:** Richard Wenzel (USA)  
Wing Hong Seto (China)

#### **Nosocomial Infections and Infection Control: Contrasting Perspectives from Developed vs. Developing Countries**

Richard Wenzel (USA)

#### **Minimizing Surgical Site Infections in Low-Resource Settings**

Mike Whitby (Australia)

#### **The Contribution of Infection Control to Managing Antibiotic Resistance**

Moi-Lin Ling (Singapore)

#### **Relative Contributions of Technology and Behavior Changes for Infection Control Outcomes**

Wing Hong Seto (China)

### **The Global Threat of Dengue—Desperately Seeking Solutions**

**Co-Chairs:** Vincent Chow (Singapore)  
Gustavo Kouri (Cuba)

#### **Epidemic Dengue/Dengue Hemorrhagic Fever as a Global Public Health Problem in the 21st Century**

Duane J. Gubler (USA)

#### **New Developments and Challenges in the Diagnosis of Dengue**

María G. Guzmán (Cuba)

#### **Determinants of Dengue Viral Virulence**

Vincent Chow (Singapore)

#### **Strategies for Development of Vaccines Against Dengue**

Vincent Deubel (France)

# 10th International Congress on Infectious Diseases • Preliminary Program

March 11–14, 2002 • Raffles City Convention Centre • Singapore

## Targeting the Pre-Membrane and Envelope Antigens to MHC Class II Compartment Enhances Neutralizing Antibody Response to a Dengue DNA Vaccine

Thomas August (USA)

## Problems and Progress in Malaria Treatment and Prevention in South East Asia

*Chair:* Nicholas Paton (Singapore)

### Malaria on Islands: Evolutionary Approaches to Control

Akira Kaneko (Japan)

### New Agents for Malaria Treatment and Prophylaxis

Sornchai Looareesuwan (Thailand)

### Chloroquine-Resistant Vivax: Epidemiology and Treatment Options

Kevin Baird (USA)

### How Close is an Effective Malaria Vaccine?

Geoff Targett (United Kingdom)

## HIV in the Asian Pacific Region

*Co-Chairs:* Yee Sin Leo (Singapore)

Christopher Lee (Malaysia)

### Epidemiology of HIV and AIDS in the Asian Pacific Region

Christopher Lee (Malaysia)

### Accessibility of Care and Treatment of HIV and AIDS in the Asian Pacific Region

Nicholas Paton (Singapore)

### Antiretroviral Therapy in Resource-Limited Settings: The Thai Experience

Kiat Ruxurontham (Thailand)

### Managing Opportunistic Infections in Resource-Limited Areas

Roberto Badaró (Brazil)

## Emerging Infections: The Strategy for Identifying New Pathogens

*Organized in collaboration with the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)*

*Co-Chairs:* Didier Raoult (France)

Carl Erik Nord (Sweden)

### The Role of Electron Microscopy

Alan Curry (United Kingdom)

### The Role of Culture

Didier Raoult (France)

### The Role of Serology

Matti Valtonen (Finland)

### The Role of Molecular Biology

David Relman (USA)

## Complete Genome Sequencing: What does it Teach Us?

*Co-Chairs:* Didier Raoult (France)

Keryn Christiansen (Australia)

### Comparative Genomics of *Bartonella henselae* and *Bartonella quintana*

Siv Andersson (Sweden)

### *Neisseria meningitidis*

Rino Rappuoli (Italy)

## Gene Expression and Functional Analysis with *Mycoplasma pneumoniae*

Richard Herrmann (Germany)

## *Rickettsia conorii* versus *Rickettsia prowazekii*: Lessons of Comparative Genomics

Jean-Michel Claverie (France)

## New Trends in Fungal Infections

*Co-Chairs:* Vladimír Krčméry (Slovakia)

Slavko Schönwald (Croatia)

### Emerging Invasive Fungal Infections in Children and Adults

Vladimír Krčméry (Slovakia)

### Preventive Strategies vs. Preemptive Therapy: Fungal Infection in the Surgical ICU

Jorge Garbino (Switzerland)

### Management of Penicilliosis in Southeast Asia

Thira Sirisanthana (Thailand)

### Management of Fungal Infection in HIV Patients without Access to HAART

Murat Akova (Turkey)

### Overview of Echinocandin Activity in the Treatment of Fungal Infections

Johan Maertens (Belgium)

## The Potential Global Impact of the Pneumococcal Conjugate Vaccines

*Co-Chairs:* Ron Dagan (Israel)

Keith Klugman (USA)

### Efficacy and Effectiveness of Pneumococcal Conjugate Vaccines—Global Perspectives

Keith Klugman (USA)

### Carriage, Transmission and Spread of *S. pneumoniae*: The Impact of Conjugate Vaccines

Ron Dagan (Israel)

### The Global Acceptance and Availability of Pneumococcal Conjugate Vaccines for the First Decade of the 21st Century

Kim Mulholland (Australia)

## New Understandings in the Pathophysiology and Treatment of Bacterial Meningitis

*Co-Chairs:* Carla Odio (Costa Rica)

Salah A. Ibrahim (Sudan)

### The Changing Pneumococcal Surface: Invasion and Virulence

Elaine Tuomanen (USA)

### Bacterial Translocation of the Brain-Blood Barrier

Kwang Sik Kim (USA)

### Present and Future of Adjuvant Therapy for Bacterial Meningitis

Joerg R. Weber (Germany)

### Fluid Restriction and Intracranial Pressure During Bacterial Meningitis: To Restrict Fluids or Not

Sunit Singhi (India)

### Current Antimicrobial Therapy for Bacterial Meningitis

Carla Odio (Costa Rica)



## SYMPOSIA



## SYMPOSIA

# 10th International Congress on Infectious Diseases • Preliminary Program

March 11–14, 2002 • Raffles City Convention Centre • Singapore

### Melioidosis

**Co-Chairs:** Brenda Ang (Singapore)  
Mahbubur Rahman (Bangladesh)

**Melioidosis: Pathogenesis and Clinical Features**  
Nicholas J. White (Thailand)

**Molecular Detection of *Burkholderia pseudomallei***  
May Ann Lee (Singapore)

**Other than Humans—Melioidosis in Animals**  
Paolo Martelli (Singapore)

**Treatment of Melioidosis—  
Where Are We Now?**  
Yupin Suputtamongkol (Thailand)

### Antibiotic Use in Pediatric Respiratory Infections: Changes in Risks, Attitudes, and Guidelines in the New Millennium

**Co-Chairs:** Chia-Yin Chong (Singapore)  
Ken Mcintosh (USA)

**The Emergence of Resistance in Respiratory  
Bacterial Pathogens and the Relation to  
Antibiotic Use**  
Ron Dagan (Israel)

**The Judicious Use of Antibiotics in Pediatrics:  
A New Initiative by the American Academy of  
Pediatrics and the Centers for Disease Control**  
Scott Dowell (Thailand)

**Responsible Antimicrobial Treatment of  
Childhood Respiratory Infections—Choice  
of Agent and Length of Treatment**  
Heikki Peltola (Finland)

**Changes in Antibiotic Use in Pediatrics with  
Widespread Use of Conjugated Bacterial  
Vaccines**  
Kim Mulholland (Australia)

**The WHO Campaign for Management of  
ARI: Its Effect on Antibiotic Resistance**  
Jacob John (India)

### New Frontiers in the Management of Chronic Hepatitis C: Therapeutic Innovations and Clinical Benefits

**Chair:** Franco Paradisi (Italy)

**Diagnosis and Monitoring of HCV Infection**  
Evangelista Sagnelli (Italy)

**The Efficacy of Antiviral Therapy for  
Prevention of Hepatocellular Carcinoma and  
Improvement in Mortality**  
Masao Omata (Japan)

**Which Treatment for Patients with HCV  
Infection and Compensated Cirrhosis**  
E. Jenny Heathcote (Canada)

**Mechanisms of Antiviral Treatment and  
Possible Reasons for Failure in Chronic  
Hepatitis C Virus Infection**  
Howard C. Thomas (United Kingdom)

### Vaccine Preventable Diseases—Successes and Ongoing Challenges

**Co-Chairs:** Heikki Peltola (Finland)  
Frank Shann (Australia)

**Global Magnitude of Vaccine Preventable  
Mortality in Children**  
Frank Shann (Australia)

**What Do Children Gain from Pneumococcal  
and Hib Conjugates?**  
Heikki Peltola (Finland)

**20 Years of Experience in Hepatitis B  
Vaccination**  
Francis André (Belgium)

**New Vaccines, New Approaches: What EPI  
Should be Doing to Further Reduce Vaccine  
Preventable Diseases Over the Next Five Years**  
Ken Mcintosh (USA)

### Towards Controlling Antimicrobial Use and Resistance in Low-Income Countries

*Organized in collaboration with the Alliance for the  
Prudent Use of Antibiotics (APUA)*

**Chair:** Anibal Sosa (USA)

**Epidemiology of Antimicrobial Resistance  
in Low-Income Countries**  
Eduardo Gotuzzo (Peru)

**Factors Involved in the Emergence and  
Diffusion of Antimicrobial Resistance in  
Low-Income Countries**  
Alessandro Bartoloni (Italy)

**Detecting Antibiotic Resistance in Low-  
Resource Settings**  
John Turnidge (Australia)

**Rational Antibiotic Use in Low-Resource  
Settings: Practices and Policies that Work**  
Atef Shibl (Saudi Arabia)

**APUA Country-Specific Antibiotic  
Regulation Strategy: Lessons Learned in  
Latin America, the Caribbean and the  
Importance of the Guadalajara Declaration**  
Anibal Sosa (USA)

### New Challenges in Tuberculosis Control

**Co-Chairs:** Timothy Brewer (USA)  
Thelma Tupasi (Philippines)

**The Role of Molecular Epidemiology in the  
Evaluation of Tuberculosis Control Efforts**  
Dao Nguyen (Canada)

**Management of MDR-TB in a Low-Resource  
National Program**  
Eduardo Gotuzzo (Peru)

**Treatment of Latent TB Infection for TB  
Control in HIV-Endemic Settings**  
Alwyn Mwinga (Zambia)

**Beyond National Programs: The Role of  
Private and Non-Profit Organizations in  
TB Control**  
Mukund Uplekar (Switzerland)

### Health Impact of Foodborne Pathogens

*Organized in collaboration with the Centers for Disease  
Control and Prevention (CDC)*

**Co-Chairs:** Robert Tauxe (USA)  
Hannes Pichler (Austria)

**Non-typhoid *Salmonella* as a  
Foodborne Pathogen**  
Sayomporn Sirinavin (Thailand)

**The Public Health Impact of *Campylobacter***  
Robert Tauxe (USA)



# 10th International Congress on Infectious Diseases • Preliminary Program

March 11–14, 2002 • Raffles City Convention Centre • Singapore

## **An Emerging Foodborne Pathogen: Bovine Spongiform Encephalopathy**

Maura Ricketts (Switzerland)

## ***E. coli* 0157: H7: Understanding a Potentially Deadly Food Borne Disease**

Haruo Watanabe (Japan)

## **Recent Advances in the Treatment of Chronic Hepatitis B Infection**

*Co-Chairs:* John S. Tam (China)

David Mutimer (United Kingdom)

## **Present and Future Treatments of Chronic Hepatitis B Infection: An Update**

Nancy W.Y. Leung (China)

## **Antiviral Therapy for Hepatitis B Virus Infection in Liver Transplantation**

David Mutimer (United Kingdom)

## **Hepatitis B Virus Mutations and Antiviral Treatment**

William F. Carman (United Kingdom)

## **Treatment Options for HBV-Associated Decompensated Liver Diseases**

E. Jenny Heathcote (Canada)

## **Immune Therapy of Hepatitis B Virus Chronic Infection**

Stanislas Pol (France)

## **Appropriate Use of Antibiotics and its Impact on Resistance Development**

*Co-Chairs:* Stephen Zinner (USA)

Kwen-Tay Luh (Taiwan)

## **Globalization of Antimicrobial Resistance- Epidemiological Challenges**

Donald Low (Canada)

## **Infectious Disease/Population Dynamics Perspective: Consequences of Action and Inaction**

Bruce Levin (USA)

## **PK/PD Perspective: Does Dose Matter?**

Richard Wise (United Kingdom)

## **Physician's Perspective: Life at the Sharp End of Prescribing**

William Holmes (United Kingdom)

## **Immunomodulators and Combination Therapy for Hepatitis C**

*Chair:* Roger G. Finch (United Kingdom)

## **New Combination Regimens for Difficult- to-Treat Chronic Hepatitis C Patients**

Stefan Zeuzem (Germany)

## **Which Patients Could Benefit from PEG Interferon plus Ribavirin Combination?**

Giovanni B. Gaeta (Italy)

## **Pegylated Interferons in the Treatment of HCV/HIV Coinfected Patients**

Teresa Santantonio (Italy)

## **Preventing Histologic Progression in Patients with Chronic Hepatitis C Virus Infection with Maintenance Therapy Utilizing**

## **Peginterferon: The NIH HALT-C Trial**

Mitchell Shiffman (USA)

## **Truth or Coincidence: Chronic Sequelae of Infectious Diseases**

*Organized in collaboration with the International Society  
of Chemotherapy*

*Co-Chairs:* Jean-Paul Butzler (Belgium)

Jean-Claude Pechère (Switzerland)

## ***Campylobacter jejuni* and Guillain-Barré Syndrome**

Nobuhiro Yuki (Japan)

## **Hemolytic Uremic Syndrome and *E. coli***

Yoshifumi Takeda (Japan)

## **The Hypothetical Association between Multiple Sclerosis and Infection**

Jean-Claude Pechère (Switzerland)

## ***Helicobacter pylori* and Cancer**

Martin J. Blaser (USA)

## **Atherosclerosis and *Chlamydia pneumoniae***

Sandeep Gupta (United Kingdom)

## **Antiretroviral Therapy for HIV**

*Co-Chairs:* Pedro Cahn (Argentina)

Kiat Ruxurungtham (Thailand)

## **When Should You Initiate Antiretroviral Therapy?**

Pedro Cahn (Argentina)

## **Blood Monitoring of Antiretroviral Drug Levels: Their Role in Clinical Practice**

John G. Gerber (USA)

## **Antiretroviral Toxicities: Recognition and Management**

Andrew Carr (Australia)

## **Planned Treatment Interruptions**

Veronika Miller (USA)

## **Update on Biomedical Interventions to Prevent HIV Transmission**

*Co-Chairs:* Kenneth H. Mayer (USA)

Soh Ha Chan (Singapore)

## **The Search for an Anti-HIV Vaccine**

Jose Esparza (Switzerland)

## **Treating STDs to Decrease HIV Transmission**

Allan Ronald (Canada)

## **Topical Microbicides to Decrease HIV Transmission**

Salim Abdool Karim (South Africa)

## **The Use of Antiretroviral Therapy (ART) to Decrease HIV Transmission**

Kenneth H. Mayer (USA)

## **Pandemic Influenza: From Molecular Pathogenesis to Global Preparedness**

*Co-Chairs:* Klaus Stöhr (Switzerland)

Nobuhiko Okabe (Japan)

## **Influenza Pandemics and Epidemics**

Yoshihiro Kawaoka (Japan)

## **Antiviral Therapy: What to Use and When for Prevention and Treatment of Influenza**

Arnold Monto (USA)

## **Pandemic Influenza and the Global Vaccine Supply**

David Fedson (France)



## SYMPOSIA



## SYMPOSIA

# 10th International Congress on Infectious Diseases • Preliminary Program

March 11–14, 2002 • Raffles City Convention Centre • Singapore

## How is the Global Public Health Community Prepared for the Next Pandemic?

Klaus Stöhr (Switzerland)

## Vaccines—New Development

**Co-Chairs:** Jingoro Shimada (Japan)  
Dennis Kasper (USA)

## New Developments in Inactivated and Live Influenza Vaccines

(speaker to be confirmed)

## Vaccines Against Group B *Streptococcus*—A Serious Neonatal Pathogen

Dennis Kasper (USA)

## Immunologic and Viral Challenges to Developing an HIV Vaccine

Mitsuo Honda (Japan)

## DNA Vaccines Against Japanese Encephalitis and Dengue

Eiji Konishi (Japan)

## Ketolides as Potential Therapeutic Agents in Areas of High Prevalence of Antibiotic Resistance in *S. pneumoniae*

**Chair:** Daryl Hoban (Canada)

## Prevalence of *S. pneumoniae* Resistance to Beta-Lactams, Macrolides and Fluoroquinolones in the Far East

Mitsuo Kaku (Japan)

## What Drives Resistance?—Social, Economic, and Political Factors

John McGowan (USA)

## How Pharmacokinetics and Pharmacodynamics Determine Outcome—Have We Learned Any Lessons?

David Nicolau (USA)

## Macrolide Resistance in *Streptococcus pneumoniae*: Implications for Ketolides

Daryl Hoban (Canada)

## Therapeutic Efficacy of New Agents Against Resistant Bacteria—How do Ketolides Compare?

Ralf René Reinert (Germany)

## Confronting Pediatric HIV/AIDS Globally

*Organized in collaboration with UNAIDS*

**Co-Chairs:** Connie Osborne (Switzerland)  
Chia-Yin Chong (Singapore)

## The Treatment of Pediatric HIV in Low-Resource Settings

Connie Osborne (Switzerland)

## Strategies for Initial Therapies and Late Modifications in Children Infected with HIV

Jack Levy (Belgium)

## Low-Cost Antiretroviral Treatments to Prevent Maternal-to-Child Transmission of AIDS

Philippe Lepage (Belgium)

## Enabling AIDS Orphans to Achieve Healthy Productive Adulthood: Affordable Strategies that Work

Matthew Hodge (USA)

## The Global Extension of Care for Persons with HIV/AIDS

*Organized in collaboration with the John E. Fogarty International Center—National Institutes of Health (NIH)*

**Co-Chairs:** Pierce Gardner (USA)  
N. Kumarasamy (India)

## Challenges and Opportunities to the Global Implementation of HIV Prevention and Treatment Programs

Harold Jaffe (USA)

## Introducing Widespread HIV/AIDS Treatment: Implications for the Emergence of Antiretroviral Resistance

Roy Anderson (United Kingdom)

## Making HIV Prevention and Treatment Work on a National Scale: Lessons from Uganda

Peter Mugenyi (Uganda)

## Global AIDS Care and Prevention in a Low Resource Setting: How Does It Happen?

Jean W. Pape (Haiti)

## Vaccination of the Millennium Babies

**Co-Chairs:** Stanley Plotkin (USA)  
Tan Cheng Lim (Singapore)

## Choosing the Right Vaccine for Safer Protection

Jacob John (India)

## Acellular Pertussis Combined Vaccines: Vaccines of the Future

Michael Decker (USA)

## MMR Vaccination: Current Situation and Perspectives

Stanley Plotkin (USA)

## Vaccinating Children Against Influenza—Protecting Individuals and Communities

David Fedson (France)

## A New Approach Against Pandemics

**Co-Chairs:** Ai Ee Ling (Singapore)  
Helen Oh (Singapore)

## Flu Situation in South East Asia

Ai Ee Ling (Singapore)

## Pandemics—Past and Future

Karl Nicholson (United Kingdom)

## Clinical Experience with an Adjuvanted Influenza Vaccine—First Choice Flu Vaccine for Elderly

Audino Podda (Italy)

## Cost Effectiveness of Influenza Vaccination

James Piercy (United Kingdom)

## Pertussis Beyond Childhood: Meeting the Need to Boost

**Co-Chairs:** Hans Bock (Singapore)  
H.K. Cheng (Singapore)

## Pertussis: The Underestimated Disease

James Cherry (USA)

## Acellular Pertussis Vaccines for Use beyond Childhood

Jussi Mertsola (Finland)

## dTpa Booster Vaccination of 4- to 6-Year-Old DTPw-Primed Subjects

Yong Poovorawan (Thailand)

## Booster Vaccination at 4–6 Years in DTPa-Primed Children

Terry Nolan (Australia)



# 10th International Congress on Infectious Diseases • Preliminary Program

March 11–14, 2002 • Raffles City Convention Centre • Singapore

**Recommendation for Pertussis Vaccination**  
Wirsing Von König (Germany)

## Controversies in the Treatment of Lower Respiratory Tract Infections

Chair: Thomas File, USA

**Chlamydia and Mycoplasma: Do They Matter?**  
Francesco Blasi (Italy)

**Prevalence of Atypical Pathogens in Asia—Plans for a Surveillance Study**  
Yuet-Meng Cheong (Malaysia)

**What is the Impact of Pneumococcal Resistance**  
Guy Amsden (USA)

**RTI Guidelines—East Versus West**  
Thomas File (USA)

## Strategies to Help Control the Growing Global Threat of Antibiotic Resistance in Hospital-Acquired Infections

Chair: Victor K.E. Lim, Malaysia

**The Growing Problem of Resistance in the Hospital Setting**  
Jae-Hoon Song (Republic of Korea)

**Management of Healthcare-Associated Gram-Positive Pathogens Using Antimicrobial Agents as a Control Strategy**  
Lance Peterson (USA)

**The Growing Problem of Gram-Negative Resistance in the Hospital Setting and Strategies to Help Minimize the Problem**  
David Jay Weber (USA)

## Prevention of Haemophilus influenzae Disease in Asia: Country and Regional Experiences to Guide Vaccine Introduction

Co-Chairs: Kim Mulholland (Australia)  
Joel I. Ward (USA)

**Global Importance of Preventing Haemophilus influenzae type b Disease**  
Joel I. Ward (USA)

**Incidence of Haemophilus influenzae Type b (Hib) Meningitis in Two Provinces of Thailand 2000–2001**  
Sophie Treleaven (United Kingdom)

**Epidemiologic Population-Based Surveillance for Hib Disease in China, Korea and Vietnam**  
Paul Kilgore (Republic of Korea)

**The Proportion of Radiologically-Confirmed and Other Pneumonias Due to Haemophilus influenzae Type b on Lombok Island, Indonesia, Using Haemophilus influenzae Type b Conjugate Vaccine as a Probe: Status Report**  
Agustinus Sutanto (Indonesia)

**Programmatic Considerations and Paradigms for Hib Vaccine Introduction in Asia**  
Jay Wenger (Switzerland)

**Summary and Future Directions**  
Kim Mulholland (Australia)

**New Advances in Clinical Microbiology**  
Chair: Augustine Cheng (China)  
Kiat Ruxurontham (Thailand)

**Microbial Signaling and Pathogenicity**  
Andreas Podbielski (Germany)

**Microarray-Based Mutational Analysis: Genetic Basis for Predisposition and Resistance to Disease**  
Calvin C.P. Pang (China)

**Low-Density Microarrays: A Flexible Tool for Clinical Diagnostics**  
Tim Tiemann (USA)

**Diagnosis, Sensitivity Testing and Identification of Stage of Disease in Tuberculosis—Applications of Reporter Technology**  
Anil K. Tyagi (India)

## Update on Anaerobes

*Organized in collaboration with the International Society for Anaerobic Bacteria (ISAB)*

Co-Chairs: Andrew B. Onderdonk (USA)  
Pramod Shah (Germany)

**The Role of Immunomodulators in Sepsis**  
Arthur O. Tzianabos (USA)

**New Antimicrobial Therapy for Anaerobic Infections**  
Carl Erik Nord (Sweden)

**The Role of Intestinal Microflora in Development of Childhood Allergies**  
Marika Mikelsaar (Estonia)

**Update on Clostridium difficile and Antibiotic Associated Colitis**  
Arne Rodloff (Germany)

## SYMPOSIA UNDER DEVELOPMENT:

### Sexually Transmitted Diseases

Changing Epidemiology with Emphasis on *N. gonorrhoeae*

New Understandings in Interactions Between Herpes and HIV

M. genitalium: An Emerging Newly Recognized Pathogen

Training Pharmacists to Manage and Prevent STD's—A Health Services RCT from Peru

### Bioterrorism

## ISID Educational and Training Programs Deadlines Reminder

### ISID Scientific Exchange Fellowship

Closing date for applications: March 1, 2002

### Swiss Society for Infectious Diseases and ISID Infectious Disease Research Fellowship

Closing date for applications: March 1, 2002

### ISID Small Grants

Closing date for applications: April 1, 2002

Information about these programs and application instructions are available on the Programs section of the ISID web site. URL: <http://www.isid.org/programs/>



Jung Soo Kim



Dr. David Patrick



Dr. Gunay Saner

## Aventis Pasteur Awards for Communicable Disease and Epidemiology

The Society gratefully acknowledges the support of AVENTIS PASTEUR, which made these awards possible.

### AVENTIS 'OTHER REGION'

#### Dr. Jung Soo Kim

Dr. Jung Soo Kim was born in Korea. After receiving his MD in 1975 from Yonsei University College of Medicine, he completed his pediatric residency at Yonsei University's Severance Hospital, and obtained his PhD in 1983, writing on "Diagnostic efficacy of ELISA and IFA in giardiasis." Since 1980, he has been on staff in the pediatrics department at Chonbuk National University Medical School. From 1984 to 1985, Dr. Kim worked at the Harbor-UCLA Medical Center in Los Angeles, where he studied the serologic responses to *M. tuberculosis* and *H. influenzae* type B. In 1998, Dr. Kim joined the International Vaccine Institute, where in collaboration with the Harbor-UCLA Medical Center in Los Angeles, he is conducting a population-based study of invasive bacterial diseases in Korea. ❖

### AVENTIS NORTH AMERICA

#### Dr. David Patrick

Dr. David Patrick is Associate Professor of Health Care and Epidemiology and Director of Communicable Diseases Epidemiology Services at the University of British Columbia's Centre for Disease Control. After completing medical school with a silver medal at the University of Ottawa in 1986, he went on to specialize in internal medicine and infectious diseases at the Universities of Ottawa and British Columbia. He completed a Masters in Health Science at UBC in 1994.

Between 1991 and 1999, Dr. Patrick was the Associate Director for STD/AIDS Control at the UBC Centre for Disease Control. He participated in clinical care, clinical and epidemiological research of STDs and HIV, and chaired and edited the Canadian STD Guidelines.

Since his appointment as Director of Communicable Diseases Epidemiology at the Centre his focus has become surveillance, outbreak investigation, and the development of interdisciplinary approaches to the control of infectious diseases. ❖

### AVENTIS EUROPE

#### Dr. Gunay Saner

Dr. Gunay Saner was born in Manisa, Turkey. She received her MD and completed her residency in pediatrics at Istanbul University School of Medicine, where she worked until 1973. She studied as Fulbright Senior Scholar at the Agricultural Research Center of Johns Hopkins University in the US, where she concentrated on chromium nutrition in health and disease. After returning to Istanbul School of Medicine, she helped found the Department of Pediatric Gastroenterology and Hepatology and the Pediatric Endoscopy Laboratory in 1989; she headed the department until 1997. Dr. Saner and her colleagues have been conducting studies on *Helicobacter pylori* and chronic hepatitis B and C infections in Turkish children since 1995. She is currently the director of the Istanbul University Institute of Child Health. ❖

**Please be sure to attend the ProMED-mail demonstration at the 10th ICID.**

**Date:** Wednesday, March 13, 2002

**Time:** 13.30 to 14.30

**Location:** VIP Lounge

**A Light Lunch Will Be Provided**



## Chiron Awards for Epidemiology of Infectious Diseases

The Society gratefully acknowledges the support of CHIRON, which made these awards possible.

### Dr. Dhrubaa Ghosh

Dr. Dhrubaa Ghosh graduated from the University of Calcutta in India. Her doctoral work in molecular parasitology, specifically studying *Plasmodium falciparum*, was carried out at the Malaria Research Center, an institute of the Indian Council of Medical Research. She earned her Ph.D. from the University of Delhi in 1993. During the initial phases of her post-doctoral career, she worked on yeast genetics at the Molecular Biology Laboratory of Jawaharlal Nehru University, New Delhi, focusing on the genes involved in the mating pathway of *Candida albicans*. For a brief period, she taught graduate students in a college of the University of Delhi.


Since 1997, she has been pursuing postdoctoral research, mainly on Enteroviruses, at the Department of Microbiology at the All India Institute of Medical Sciences (AIIMS), New Delhi. She has also been working on the molecular aspects of other viruses such as Caliciviruses and Hepatitis C. However, her main area of interest has been the molecular tracking of Poliovirus strains in India. Dr. Ghosh has been working on this problem in close association with the National Institute of Communicable Diseases, which is one of the WHO reference centers for Polioviruses in India. She is a Senior Research Associate of the Council of Scientific and Industrial Research, India, and continues her work at AIIMS. ❖

### Dr. Archana Sud

Born in India, Dr. Archana Sud completed her medical schooling and later obtained her MD in Internal Medicine from Christian Medical College, Ludhiana, Punjab, India in 1988. She then worked on the faculty of Christian Medical College, Vellore, Tamil Nadu, as well as at Ludhiana, Punjab, India. She joined the Postgraduate Institute of Medical Education and Research, Chandigarh, India in 1994, where she is presently an Associate Professor of Internal Medicine. She has over 50 research publications to her credit mostly in the field of infectious diseases, particularly HIV and associated opportunistic infections. She is a member of the Target Resource Group of National AIDS Control Organization for the management of HIV infection in India. Currently she is pursuing research on epidemiology of HIV infection as a Clinical Research Fellow at the Sexually Transmitted Infections Research Center of the Westmead Hospital, New South Wales, Australia. ❖



Dr. Dhrubaa Ghosh



Dr. Archana Sud

**ISID would like to acknowledge the following**

## SPONSORS

### 10th International Congress on Infectious Diseases

#### CONGRESS BENEFACTOR

Merck Vaccine Division

#### PREMIER SPONSORS

AstraZeneca

Aventis

Aventis Pasteur

Bayer AG

Chiron Vaccines

Wyeth-Ayerst Pharmaceuticals

#### SPONSORS

Baxter Vaccine AG

Bristol-Myers Squibb Company

Eli Lilly

F. Hoffmann-La Roche and Roch Laboratories Inc.

GlaxoSmithKline

Motorola

Pfizer Pharmaceuticals Group, Pfizer Inc.

Pharmacia & Upjohn Co.

Roche Molecular Systems

Schering-Plough Corporation

Singapore Airlines

Singapore Tourism Board